Those taking celecoxib showed a moderate benefit, but the results, which were published in 2021, were not statistically significant. Evidence has since emerged suggesting that anti-inflammatory drugs ...

Although risk for recurrent adenomas was lowered, this benefit might be outweighed by adverse cardiovascular effects. Because cyclooxygenase 2 (COX-2) is overexpressed in colorectal adenomatous polyps ...

A data analysis from a randomized clinical trial for stage 3 colon cancer patients by investigators at Dana-Farber Brigham Cancer Center found that patients with evidence of residual cancer in their ...

Aug. 4, 2005 — The U.S. Food and Drug Administration (FDA) has approved valsartan to reduce cardiovascular mortality in patients with left ventricular dysfunction/failure following a myocardial ...

Temporal trends of mortality due to laryngeal cancer among older adults in United States: A CDC WONDER analysis on gender, race, and geographical disparities. This is an ASCO Meeting Abstract from the ...